Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Conditions
Interventions
AVP-786
Placebo
Locations
106
United States
Clinical Research Site #840-020
Phoenix, Arizona, United States
Clinical Research Site #840-047
Anaheim, California, United States
Clinical Research Site #840-090
Costa Mesa, California, United States
Clinical Research Site #840-059
Lafayette, California, United States
Clinical Research Site #840-048
Lomita, California, United States
Clinical Research Site #840-095
Long Beach, California, United States
Start Date
September 11, 2020
Primary Completion Date
June 28, 2024
Completion Date
June 28, 2024
Last Updated
May 30, 2025
NCT02446132
NCT03393520
NCT04797715
NCT02442765
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions